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Abstract : Purpose We assessed the efficacy of palonosetron (PAL) in comparison to granisetron (GRA) for the 
treatment of CINV using the self-assessment questionnaires. In addition, we analyzed the serum levels of emetic 
various biomarkers. Methods We conducted a randomized study of 70 patients naïve to chemotherapy. The pri-
mary endpoint was the late phase score on the MAT questionnaire. The plasma concentrations of the biomarkers 
were measured on days 1 and 3. Results There were no statistical differences in the scores on the questionnaires, 
but the mean values in response to PAL were higher than those in response to GRA. The value of ghrelin on day 1 
was significantly higher for GRA than for PAL. Conclusions For the primary endpoint, the score of the late phase 
on the MAT questionnaire was not statistically different between the PAL and GRA treatment groups. Further 
studies are needed to clarify the role of ghrelin for the treatment of CINV. J. Med. Invest. 66 : 269-274, August, 2019




Chemotherapy-induced nausea and vomiting (CINV) is among 
the most feared and distressing side effects of chemotherapy for 
cancer patients. Inadequate control of CINV may cause treat-
ment delay or discontinuation and impair the patient’s quality of 
life (QOL). Oncologists should recognize that antiemetic therapy 
is important for the completion of chemotherapy while maintain-
ing the QOL of the patients. The antiemetic guidelines provided 
by American Society of Clinical Oncology (ASCO) (1), National 
Comprehensive Cancer Network (NCCN) (2), and the Multi-
national Association of Support Care in Cancer (MASCC) (3) 
allow us to control CINV with appropriate antiemetic therapy. 
These current antiemetic guidelines classify the risks of CINV 
with anticancer drug by the regimen (e.g., high emetic risk che-
motherapy (HEC), moderate emetic risk chemotherapy (MEC), 
low and minimal emetic risk chemotherapy) and the occurring 
phase (acute, delayed and anticipatory nausea and vomiting). 
Moreover, the guidelines list the recommended antiemetic drugs 
while showing the correct dosage.
CINV has physiologic mechanisms in each occurring phases, 
and various guidelines are recommended to choose the drug 
to use accordingly (1-3). For instance, it is thought that the 
release of serotonin (5-HT) from enterochromaffin cells in the 
small intestine is related to acute phase CINV. 5-HT3 receptor 
antagonists (RAs) are reported to have complete response (CR) 
rates (i.e., no emesis, no use of rescue medication) of 50-70% (4-5) 
when using these drugs as single agents for antiemetic therapy 
of acute CINV (occurring within 24 hours of chemotherapy) in 
patients receiving MEC. However, it has been reported in the 
prevention of delayed CINV (occurring > 24 hours after che-
motherapy) that the effectiveness is low even if 5-HT3 RAs are 
administered together with a steroid (6). 
Recently, new antiemetic agents have been developed such 
as the 5-HT3RA, palonosetron (PAL) (7-9), and the neuroki-
nin-1 (NK1) RA (10-12), aprepitant. PAL is a highly potent, 
second-generation selective 5-HT3 RA. It has been shown to 
have an approximately 100-fold stronger binding affinity for the 
5-HT3 receptor compared with other 5-HT3 RAs and an extended 
plasma elimination half-life of approximately 40 hours (7). The 
PROTECT study (8), a phase III trial, showed that PAL with 
dexamethasone exerts efficacy against CINV which is non-in-
ferior to that of granisetron (GRA) with dexamethasone in the 
acute phase and is better than that of GRA in the delayed phase. 
Aprepitant is the first approved substance P (SP)/NK1-RA, and 
it has been shown to significantly improve the prevention of 
acute and delayed CINV for use in combination with a 5-HT3RA 
and dexamethasone (10-12). 
While the strategy for the prevention of CINV is in progress, 
the self-assessment of patients using questionnaires is attractive 
because questionnaires can estimate the patient’s QOL objec-
tively. The MASCC Antiemesis Tool (MAT) (13) was developed 
as a tool for subjective patient self-evaluation of CINV in 2004 
in which the patient can easily evaluate the onset time of CINV 
(14). The Functional Living Index-Emesis (FLIE) questionnaire 
is a validated patient-reported measure of the impact of CINV 
on daily living (15-16). However, there are few clinical trials that 
have examined these questionnaires as a major index of CINV 
evaluation. 
On the other hand, it is well known that various emetic 
biomarkers, such as 5-HIAA, SP and ghrelin, affect emesis 
expression or appetite suppression. Serotonin (5-HIAA is a one 
of the metabolites of serotonin) has long been appreciated as the 
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primary mediator of acute vomiting, a conclusion consistent with 
the efficacy of 5-HT3 RAs in treating early phase CINV (17-18). 
SP is a regulatory peptide found in areas of the central nervous 
system and the gastrointestinal tract and known to cause CINV 
by binding to the NK-1 receptor of the vagal afferents (19-21). 
Ghrelin is a growth-hormone-releasing acylated peptide predom-
inately produced by gastric endocrine cells and known to have 
an intense appetite-enhancing effect in addition to the growth 
hormone secretion-promoting effect (22-24). Moreover, the asso-
ciation between emetic biomarkers and CINV is unclear. 
Therefore, our study was designed to evaluate the effective-
ness of PAL compared to GRA using questionnaires in standard 
antiemetic therapy, especially for delayed phase CINV in which 
the prevention of CINV is believed to be difficult. Another ob-
jective of this study was to assess the plasma biomarker levels 
(5-HIAA, substance P, ghrelin) of patients who received chemo-
therapy with antiemetic drugs. 
PATIENTS AND METHODS
Design and patients
This study was a prospective, randomized, single-center, 
comparative phase III trial. Eligible patients were 20 years of 
age or older with histologically or cytologically confirmed malig-
nant disease, chemotherapy-naive and an Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) of 0-2. Each 
patient was scheduled to receive his first course of HEC or MEC. 
The classification of HEC and MEC were according to the Japan 
Society of Clinical Oncology (JSCO) antiemetic guideline. The 
primary exclusion criteria included the following : dementia, 
planned whole brain irradiation, active infection, symptomatic 
brain metastasis, symptomatic hypercalcemia or hyponatremia. 
The primary endpoint was the score of late phase CINV on the 
MAT questionnaire. The secondary endpoints were the score of 
nausea or vomiting in the FLIE questionnaire, the proportion 
of patients that achieved a CR (defined as no emetic episode and 
no use of rescue medication) and the plasma concentrations of 
the biomarkers. Written informed consent was obtained from all 
patients in this study, which was approved by the institutional 
review board. This trial was registered with the UMIN (No. 
000005268). At the time of registration to UMIN, because there 
was a patient of lung cancer and the breast cancer to start che-
motherapy 80 patients at our hospital in a year, we set number 
of cases to 60 patients. After an examination start, because most 
of the enrolled patients were lung cancer patients, we increased 
the enrollment of the breast cancer patient in consideration of the 
balance of both groups and the study finished in 70 cases. 
Procedures
The patients were randomized 1 : 1 to either the PAL or GRA 
treatment group, which were stratified by age, gender and the 
risk of CINV for chemotherapy (HEC or MEC). The standard 
antiemetic therapy for HEC was consisted to be intravenous 
PAL (0.75 mg) or GRA (3 mg) and dexamethasone (9.9 mg) on 
day 1, followed by oral dexamethasone (8 mg daily) on days 2-4. 
Oral aprepitant (125 mg) was administered on day 1 followed by 
80 mg daily on days 2 and 3. The standard antiemetic therapy 
for MEC was consisted to be intravenous PAL (0.75 mg) or GRA 
(3 mg) and dexamethasone (9.9 mg) on day 1, followed by oral 
dexamethasone (8 mg daily) on days 2 and 3, and without oral or 
intravenous aprepitant. After chemotherapy, rescue medication 
for the treatment of nausea and vomiting was allowed for all 
patients. 
For the assessment of the biomarkers, blood samples were 
collected at 1 h and 48 h after chemotherapy, according to the re-
sults of our preliminary study (data not shown). Approximately 
4 mL of peripheral blood were divided into three tubes. For the 
measurement of active ghrelin, we used aprotinin/EDTA added 
tubes. All tubes were immediately centrifuged at 4℃, 3000 rpm 
for 10 min. The plasma was removed and stored at -80℃ until 
further use. The plasma concentration of 5-HIAA was measured 
by SRL Inc. (Tokyo, Japan) using a high-performance liquid 
chromatography system. SP (Cayman Chemical Co, Ann Arbor, 
Michigan, USA) and active ghrelin (SCETI Co Ltd, Tokyo, 
Japan) were measured using an enzyme-linked immunosorbent 
assay kit according to the protocol supplied by the manufacturer.
Assessments
We used two kinds of questionnaires to evaluate nausea and 
vomiting. The MAT questionnaire is an eight-item scale for 
the assessment of acute and delayed CINV that is completed 
once per cycle of chemotherapy (25). The validated FLIE ques-
tionnaire specifically addresses the impact of CINV on daily 
functioning and quality of life (QOL) (15-16). On days 2 and 5, 
the patients completed a MAT questionnaire to assess the effect 
of nausea or vomiting. On day 5, the patients also completed 
FLIE questionnaires. The study observation period was divid-
ed in three distinct phases : the acute phase, from the start of 
chemotherapy to 24 h post-chemotherapy administration (days 
1-2) ; the delayed phase, from 24 h to 120 h (days 2-5) post-che-
motherapy administration ; and the overall phase (days 1-5). 
Higher scores indicated more severe disease on the MAT and 
FLIE questionnaires.
Statistical analysis
Student’s t-test or the Mann Whitney U test was applied 
to assess the data. All of the statistical calculations were per-
formed using the SPSS software program, version 19 (IBM, 




Patients were evaluated between Oct. 2010 and Jan. 2013. 
Seventy patients were enrolled and randomized to the PAL or 
GRA treatment group. Table 1 shows that the patient baseline 
characteristics, including known risk factors for CINV (gender, 
Table 1　Patient characteristics
PAL (N = 35) GRA ( = 35)





68 yr50-69 18 17
≧ 70 14 14
Gender Male 22 22
Female 13 13
Risk of emesis HEC 20 19
MEC 15 16




ECOG PS 0 / 1 24 / 11 23 / 12
Previous radiotherapy Yes / No 8 / 27 4 / 31
Alcohol habits Yes / No 20 / 15 18 / 17
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alcohol consumption or history of radiation therapy), were simi-
lar between the two treatment groups. The majority of patients 
were male (44/70, 63%) with an average age of 68 years, and 
56% of the patients received a HEC regimen. The most common 
primary types of malignant disease included lung cancer (54/70, 
79%) and breast cancer (12/70, 17%).
Efficacy
For the primary endpoint, the score of the late phase on the 
MAT questionnaire was not statistically different between the 
PAL and GRA treatment groups (2.7 vs 3.5, P = 0.55) (Figure 1). 
The acute phase on the MAT questionnaire and emesis and nau-
sea on the FLIE questionnaire (Figure 1) were also not statis-
tically different between the two treatment groups. A subgroup 
analysis of each treatment group stratified by HEC and MEC 
also showed no statistically differences. While there were no 
statistical differences in the overall score of the questionnaires, 
the mean values in those receiving PAL were lower than those 
receiving GRA in both the acute and delayed phases. In addition, 
the CR (51.4% vs 48.6%) and total control (TC) (37.1% vs 40.0%) 
rates were similar during all phases among the PAL and GRA 
treatment groups (Table 2). An analysis of the questionnaires 
and the rate of total control showed that approximately 60% of 
the patients suffered from any vomiting or nausea, thus these 
patients required rescue medication throughout the observation 
period. 
Table 2　Evaluation of the responses















Acute 80.0 82.9 70.0 68.4 93.3 100
Delayed 51.4 48.6 35.0 36.8 66.7 62.5
Overall 51.4 48.6 35.0 36.8 66.7 62.5
Total
Control Overall 37.1 40.0 25.0 31.6 60.0 50.0
Complete response ; defined as no emetic episodes and no use of rescue medication
Total control ; defined as no emetic episodes, no use of rescue medication, and no nausea Acute ; 0-24 h, 
Delayed ; 24-120 h, Overall ; 0-120 h
Figure 1　Results of the questionnaires
Data are expressed as the mean ± SE.
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Biomarker assessment
The plasma concentrations of SP and 5-HIAA were not signifi-
cantly different between the PAL and GRA treatment groups on 
days 1 and 3, while the plasma ghrelin levels were significantly 
higher for GRA than PAL on day 1 (Figure 2). The ghrelin levels 
on day 3 were significantly decreased compared with on day 1 
in the GRA group. A subgroup analysis of each treatment group 
stratified by HEC and MEC, having CINV or not, and a high 




For all time points or intervals not mentioned, a similar trend 
favoring PAL compared with GRA was observed, although this 
difference did not reach statistical significance. It is especially 
important to note that at least 50% of the patients experienced 
CINV following an initial cycle of HEC and MEC, despite sub-
stantial recent progress. These patients required rescue medica-
tion throughout the observation period. In addition, the results of 
the biomarker study indicated that the plasma concentration of 
ghrelin, which is an appetite increaser hormone, may be related 
to the type or dosage of 5-HT3RA.
Our results regarding the CR and TC rates are in agreement 
with previous triple therapy studies. The reason that significant 
differences were not detected in our study is because the sample 
size was too small. However, all the scores on the questionnaires 
showed an advantage with PAL treatment. In particular, be-
cause the FLIE questionnaire is a qualifying tool for evaluating 
the QOL of the patient, the fact that PAL treatment resulted 
in higher scores is thus considered to be an important finding. 
These finding suggest the possibility that PAL is useful for QOL 
maintenance of the patients compared with GRA. The evalua-
tion of CINV is typically subjective, especially during the delayed 
phase. Clinicians tend to underestimate the incidence of nausea 
and vomiting, as well as a worsening of a patient’s QOL during 
chemotherapy, and therefore improved communication between 
medical professionals and patients regarding CINV may help 
improve the outcomes (25-26). Thus, clinicians are sometimes 
troubled with the grading decision of the adverse events of CINV 
because the evaluation is not objective. Although we adopted 
standard antiemetic therapy in this study, which complied with 
the guidelines, the FLIE questionnaire clarified that approxi-
mately half of the patients felt that their QOL was inhibited by 
CINV. The MAT and FLIE questionnaires are a short, easy, 
self-administered instrument containing two domains – one for 
nausea and one for vomiting. These questionnaires are reliable 
for assessing the patient’s QOL and easy-to-use in the clinical 
setting, thus they are useful tools for CINV management.
Various reports in the literature have shown that there is 
cross-talk between ghrelin, NK-1 and the 5-HT receptor signal-
ing pathway (27-31). Rojas et al. (28) have shown the possibility 
that 5-HT3 RAs can inhibit cisplatin-induced activation of the SP 
response. Moreover, 5-HT2C receptor gene expression may lead 
to anorexia in cisplatin-treatment patients, and administration 
of a 5-HT2C agonist inhibited hypothalamic ghrelin secretion 
(30). Recent reports indicate that both the 5-HT2C receptor 
and the 5-HT2B receptor, but not the 5-HT3 receptor, mediate 
cisplatin-induced ghrelin suppression in rodents (32). In this 
study, we showed that there was a difference in the influence on 
the plasma ghrelin level between the PAL and GRA treatment 
groups. This phenomenon may be caused by the pharmacologic 
differences of the affinity of 5-HT3 RA to the 5-HT2C or 5-HT2B 
receptor. It was thought that 5-HT3 RAs, especially GRA, might 
have the potential to increase the ghrelin level and desacylation 
through various serotonin receptors. Because half-life is short in 
GRA with 4-9 hours, it is thought that the blood concentration 
of the ghrelin of day 3 decreased briefly as for the time to affect 
Figure 2　Results of the biomarkers
Data are expressed as the mean ± SE. *Statistically significant by student’s t-test.
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5-HT receptor. Further studies are needed to clarify any differ-
ences in the effects of both 5-HT2C and 5-HT2B and also elucidate 
their influence on ghrelin secretion and the metabolism during 
5-HT3 RA treatment.
CONCLUSION
However the score of the late phase on the MAT question-
naire was not statistically different between the PAL and GRA 
treatment groups, this study provided important information on 
the clinical assessment of CINV, and demonstrated that ques-
tionnaires, such as MAT and FLIE, are helpful for improving 
patient care during cancer chemotherapy. Though we provided 
treatment according to the antiemetic guidelines as standard 
therapy, half of the patients felt that their QOL was inhibited by 
chemotherapy. Further studies should investigate the control of 
CINV over the duration of cancer therapy and should consider 
not only the CR rate during the first cycle, but also the QOL of 
all cancer patients. 
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